Information for Investors

We believe providing an individualized risk of spontaneous premature birth and other pregnancy complications is a critical first step to improving maternal and newborn health. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to meaningfully reduce healthcare costs. 

Corporate Presentation
Relevant Publications

Find the latest publications here.

Recent News
Nov 29, 2022

– Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce – SALT LAKE CITY and ARLINGTON, Va.,...

Nov 15, 2022

- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds - SALT LAKE CITY, Nov. 15, 2022 /PRNewswire/ -- Sera Prognostics...

Nov 9, 2022

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

View More

Upcoming Events
Wednesday, November 9, 2022
5:00pm - 6:00pm EST

View Past Events

Email Alerts

Sign up for our investor relations email list here.